Figure 8

Cataract treatment.

Oral product for safe therapeutic manipulation with molecular chaperones, telomeres, and telomerase biology; N-acetylcarnosine lubricant eye drops and oral product comprising carnosine, D-pantethine, or regulated/inducible molecular chaperone protein function (such as α-crystallin chaperone activity in the lens) offer potential novel therapies for reversal of (ripe) cataracts, retinal degeneration, and ocular complications of diabetes. Potential therapeutic applications of oral forms of nonhydrolyzed carnosine and their specific mechanisms to manage telomere attrition and vascular aging might help elderly patients to withstand the problems of sight-threatening eye diseases related to oxidative stress and accelerated biological aging in linked with earlier onset of diseases. Left, pronounced opacities in the lens layers prior cataract treatment; right, an appearance of the rose reflex visible through the lens, which became significantly more transparent after 5 months of combined treatment of ripe cataract with the 1% N-acetylcarnosine lubricant eye drop combined with the oral supplementation of Can-C Plus [15, 171].

© De Gruyter